4.6 Article

Nano magnetic liposomes-encapsulated parthenolide and glucose oxidase for ultra-efficient synergistic antitumor therapy

Journal

NANOTECHNOLOGY
Volume 31, Issue 35, Pages -

Publisher

IOP Publishing Ltd
DOI: 10.1088/1361-6528/ab92c8

Keywords

tumor microenvironment; synergistic antitumor; magnetic targeting; parthenolide; glucose oxidase; liposome; fenton reaction

Funding

  1. National Natural Science Foundation [21776238, 31801198]
  2. Key projects of Natural Science of Hebei Province [B2019203479]
  3. Hebei education department key project [ZD2017084]
  4. Hebei province top talents support program

Ask authors/readers for more resources

Multifunctional nanoplatforms yield extremely high synergistic therapeutic effects on the basis of low biological toxicity. Based on the unique tumor microenvironment (TME), a liposomes (Lips)-based multifunctional antitumor drug delivery system known as GOD-PTL-Lips@MNPs was synthesized for chemotherapy, chemodynamic therapy (CDT), starvation therapy, and magnetic targeting synergistic therapy. Evidence has suggested that parthenolide (PTL) can induce apoptosis and consume excessive glutathione (GSH), thereby increasing the efficacy of chemodynamic therapy. On the other hand, glucose oxidase (GOD) can consume intratumoral glucose, lower pH and increase the level of H(2)O(2)in the tumor tissue. Integrated Fe(3)O(4)magnetic nanoparticles (MNPs) containing Fe(2+)and Fe(3+)effectively catalyzes H(2)O(2)to a highly toxic hydroxyl radical (center dot OH) and provide magnetic targeting. During the course ofin vitroandin vivoexperiments, GOD-PTL-Lips@MNPs demonstrated remarkable synergistic antitumor efficacy. In particular, in mice receiving a 14 day treatment of GOD-PTL-Lips@MNPs, tumor growth was significantly inhibited, as compared with the control group. Moreover, toxicology study and histological examination demonstrated low biotoxicity of this novel therapeutic approach. In summary, our data suggests great antitumor potential for GOD-PTL-Lips@MNPs which could provide an alternative means of further improving the efficacy of anticancer therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available